A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) Who Have Completed Study IM011074 or Study IM011132
← catalyst calendarNCT06875960 · readout in 104 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 4
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
35estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-24 | actual | When the study began enrolling |
| Primary completion | 2026-12-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-01 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-14 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Systemic Lupus Erythematosus (SLE)
- Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)
Intervention
- Drug: BMS-986165
Primary outcome
what the primary-completion date above is the date OFNumber of participants treated with BMS-986165
measured Up to 2 years
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed